Do Analysts Expect Emergent Biosolutions Inc (EBS) Stock to Rise After It Is Down -30.16% in a Month?

InvestorsObserver is giving Emergent Biosolutions Inc (EBS) an Analyst Rating Rank of 5, meaning EBS is ranked higher by analysts than 5% of stocks. The average price target for EBS is $13.5 and analyst’s rate the stock as a Hold.

Wall Street analysts are rating EBS a Hold today. Find out what this means to you and get the rest of the rankings on EBS!

See Full EBS Report

Why are Analyst Ratings Important?

You can learn a lot about a company from looking at it’s financial statements and comparing them to other companies. Analysts who cover an industry in depth can add even more to your research though. They typically follow a particular sector or industry very closely. They also pay attention to and ask questions on earnings conference calls and other events where they might learn information that does show up in the numbers. InvestorsObserver takes the average rating from these analysts, and then percentile ranks those averages. This lets you compare stocks in a much more granular way than just seeing the typical five-tiered rating system used on most of Wall Street.

What's Happening With Emergent Biosolutions Inc Stock Today?

Emergent Biosolutions Inc (EBS) stock is down -0.45% while the S&P 500 is higher by 0.05% as of 10:06 AM on Thursday, Nov 9. EBS has fallen -$0.01 from the previous closing price of $2.21 on volume of 216,196 shares. Over the past year the S&P 500 has risen 16.98% while EBS has fallen -82.88%. EBS lost -$12.08 per share the over the last 12 months. Click Here to get the full Stock Report for Emergent Biosolutions Inc stock.